Hyperoxic BOLD-MRI-based characterization of breast cancer molecular subtypes is independent of the supplied amount of oxygen: A preclinical study Journal Article


Authors: Bartsch, S. J.; Ehret, V.; Friske, J.; Fröhlich, V.; Laimer-Gruber, D.; Helbich, T. H.; Pinker, K.
Article Title: Hyperoxic BOLD-MRI-based characterization of breast cancer molecular subtypes is independent of the supplied amount of oxygen: A preclinical study
Abstract: Hyperoxic BOLD-MRI targeting tumor hypoxia may provide imaging biomarkers that represent breast cancer molecular subtypes without the use of injected contrast agents. However, the diagnostic performance of hyperoxic BOLD-MRI using different levels of oxygen remains unclear. We hypothesized that molecular subtype characterization with hyperoxic BOLD-MRI is feasible independently of the amount of oxygen. Twenty-three nude mice that were inoculated into the flank with luminal A (n = 9), Her2+ (n = 5), and triple-negative (n = 9) human breast cancer cells were imaged using a 9.4 T Bruker BioSpin system. During BOLD-MRI, anesthesia was supplemented with four different levels of oxygen (normoxic: 21%; hyperoxic: 41%, 71%, 100%). The change in the spin–spin relaxation rate in relation to the normoxic state, (Formula presented.), dependent on the amount of erythrocyte-bound oxygen, was calculated using in-house MATLAB code. (Formula presented.) was significantly different between luminal A and Her2+ as well as between luminal A and triple-negative breast cancer, reflective of the less aggressive luminal A breast cancer’s ability to better deliver oxygen-rich hemoglobin to its tissue. Differences in (Formula presented.) between subtypes were independent of the amount of oxygen, with robust distinction already achieved with 41% oxygen. In conclusion, hyperoxic BOLD-MRI may be used as a biomarker for luminal A breast cancer identification without the use of exogenous contrast agents. © 2023 by the authors.
Keywords: controlled study; nonhuman; nuclear magnetic resonance imaging; mouse; oxygen; animal experiment; animal model; hemoglobin; hypoxia; erythrocyte; isoflurane; triple negative breast cancer; bold signal; oxygen concentration; hyperoxia; preclinical study; human epidermal growth factor receptor 2 positive breast cancer; luminal a breast cancer; female; article; breast cancer cell line; breast cancer molecular subtype; t1 weighted imaging; breast cancer characterization; hyperoxic bold-mri; intrinsic contrast mri
Journal Title: Diagnostics
Volume: 13
Issue: 18
ISSN: 2075-4418
Publisher: MDPI  
Date Published: 2023-09-02
Start Page: 2946
Language: English
DOI: 10.3390/diagnostics13182946
PROVIDER: scopus
PMCID: PMC10530249
PUBMED: 37761313
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record. Corresponding MSK author is Katja Pinker-- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors